Skip to main content
HR 933 107th Congress House International Affairs AIDS (Disease) Access to health care Africa (Sub-Saharan) Appropriations Commerce Competition Corporate philanthropy Developing countries Drug industry Drugs Economics and Public Finance Foreign Trade and International Finance Free trade Health Human immunodeficiency viruses Intellectual property International agencies Medical technology Patent agreements

Affordable HIV/AIDS Medicines for Poor Countries Act

Introduced: March 7, 2001 Introduced by: Waters, Maxine Democratic · California See on congress.gov
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 14, 2001
Referred to the Subcommittee on Trade.
Mar 7, 2001
Referred to the Committee on Ways and Means, and in addition to the Committee on International Relations, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 7, 2001
Introduced in House
 Plain-English summary Congressional Research Service
Affordable HIV/AIDS Medicines for Poor Countries Act - Directs the Secretary of the Treasury, the Administrator of the U.S. Agency for International Development, and the U.S. Trade Representative (USTR) to encourage developing countries (including sub-Saharan African countries) and pharmaceutical companies to make HIV/AIDS pharmaceuticals and medical technologies available to people who live in such countries without charge or at affordable prices.

Sets forth certain restrictions and limitations, including that: (1) appropriated funds made available to U.S. agencies may not be obligated to seek the revocation or revision of any intellectual property or competition law or policy of a developing country (including any sub- Saharan African country) that regulates HIV/AIDS pharmaceuticals or medical technologies if such law or policy promotes access to such drugs and technologies by the country's population; and (2) the USTR may not initiate a proceeding in the World Trade Organization (WTO) challenging any law or policy of a developing country (including a sub-Saharan African country) that promotes access by HIV/AIDS pharmaceuticals or medical technologies by the population of the country.

Requires the President to direct the U.S. representative to the WTO to urge the WTO and member countries to exempt developing countries (including sub-Saharan African countries) from the application of any provision of the Agreement on Trade-Related Aspects of Intellectual Property Rights or any other international agreement relating to intellectual property rights that would prohibit or restrict such countries from establishing or implementing any law or policy that promotes access to HIV/AIDS pharmaceuticals or medical technologies to their population.

What's happening now March 14, 2001

Referred to the Subcommittee on Trade.

 Committees of jurisdiction 3